Lumiracoxib in the management of osteoarthritis and acute pain (Q34657320)

3 August 2017

1 reference

title

Lumiracoxib in the management of osteoarthritis and acute pain (English)

1 reference

3 August 2017

0 references

0 references

Bernard Bannwarth

1

1 reference

PubMed ID

17661736

3 August 2017

Francis Bérenbaum

series ordinal

2

1 reference

PubMed ID

17661736

3 August 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

Expert Opinion on Pharmacotherapy

3 August 2017

1 reference

3 August 2017

8

1 reference

3 August 2017

10

1 reference

3 August 2017

1551-1564

1 reference

Pathogenesis and management of pain in osteoarthritis.

3 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Acetaminophen or NSAIDs for the treatment of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor on pain management and recovery of function after knee replacement: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: a qualitative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

ABC of the upper gastrointestinal tract: Indigestion and non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Do selective cyclo-oxygenase-2 inhibitors have a future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Peripheral and spinal mechanisms of antinociceptive action of lumiracoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Pharmacokinetics of lumiracoxib in plasma and synovial fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Is hirudin a potential therapeutic agent for arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Raised serum interleukin 15 levels in Kawasaki disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Lumiracoxib: pharmacokinetic and pharmacodynamic profile when coadministered with fluconazole in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Concomitant administration of lumiracoxib and a triphasic oral contraceptive does not affect contraceptive activity or pharmacokinetic profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Analgesic efficacy of single oral doses of lumiracoxib and ibuprofen in patients with postoperative dental pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

The post-operative analgesic efficacy and tolerability of lumiracoxib compared with placebo and naproxen after total knee or hip arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Lumiracoxib is effective in the treatment of episodic tension-type headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

A coxib a day won't keep the doctor away

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.10.1551

10.1517/14656566.8.10.1551

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

17661736